Utah Relay
PoliticsPublic SafetyBusinessEducationEnvironmentHealthSportsCulture
Utah Business

David Bearss

A conference session preview featuring David Bearss, CEO of Utah-based Halia Therapeutics, discussing how the Utah Population Database helps identify genetic 'outliers' to drive drug discovery, including a clinical-stage Alzheimer's therapy.

Read the full story at utahbusiness.com

Share X Facebook LinkedIn Bluesky Email

This is a summary with a link to the original. The reporting belongs to Utah Business.